SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected...
Month: November 2020
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to...
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date Complete response...
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of...
Atreca to Present at Upcoming Virtual Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on...
Sientra to Participate in Upcoming Virtual Investor Conferences
SANTA BARBARA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical...
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal...
Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
Experienced Financial Executive Brings Leadership and Public Company Expertise BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:...
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense...
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
– Manuscript highlights the importance of molecular surveillance of SARS-CoV-2 immune evasion and rational design of vaccines and antibody therapies...
Digirad Corporation to Release Third Quarter 2020 Financial Results on November 13
SUWANEE, Ga., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”), a diversified holding...
Shattuck Labs to Present Virtually at Cowen 4th Annual IO Next Summit
AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology...
Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion
ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has...
Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference
– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST – BOTHELL, WA,...
Cytokinetics Announces Six Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at the AHA Scientific Sessions 2020
Primary Results from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session Cytokinetics to Host Investor/Media Event and Webcast...
Invitation to Active Biotech’s virtual capital markets day
Active Biotech AB (publ) (ticker: ACTI) hereby invites analysts, investors and media to its virtual Capital Markets Day on November...
Progenity Announces Encouraging Preclinical Data Supporting the Potential of the Company’s Oral Drug Delivery System in Targeting the Colon
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record...
Ocugen Provides Business Update and Third Quarter 2020 Financial Results
First Gene Therapy Candidate OCU400 On Track to Enter the Clinic in 2021 MALVERN, Pa., Nov. 06, 2020 (GLOBE NEWSWIRE)...
Apollomics, Inc. Closes $124 Million Series C Financing
- Financing led by Ping An Capital - - Phase 2 SPARTA Trial for APL-101 Now Enrolling - - Phase...
Aleafia Health Successful Outdoor Harvest Accelerates Product Portfolio Expansion
Aleafia Health Port Perry Outdoor cannabis cultivation. TORONTO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC:...